Treatment Selection and Novel Agents in Chronic Lymphocytic Leukemia


Journal of Clinical Pathways spoke with Matthew Davids, MD, department of medical oncology, Dana-Farber Cancer Institute (Boston, MA), about his presentation at the latest ASH Annual Meeting and Exposition regarding the novel agents available (and in the pipeline) for the treatment of chronic lymphocytic leukemia, as well as strategies for sequencing monotherapies and deciding when to administer a combination regimen in this disease setting.

To read the podcast transcript, click here.